Cilostazol is a phosphodiesterase 3 inhibitor indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. It is available as tablets for oral use. MedsAcross supplies Cilostazol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance
Source: US FDA prescribing information
Cilostazol tablets and several of its metabolites inhibit phosphodiesterase III activity and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation, respectively. Cilostazol tablets reversibly inhibit platelet aggregation induced by a variety of stimuli, including thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress. Cardiovascular Effects: Cilostazol affects both vascular beds and cardiovascular function. It produces heterogeneous dilation of vascular beds, with greater dilation in femoral beds than in vertebral, carotid or superior mesenteric arteries. Renal arteries were not responsive to the effects of cilostazol.
Source: US FDA prescribing information
The recommended dosage of cilostazol tablets is 100 mg twice daily taken at least half an hour before or two hours after breakfast and dinner. Reduce the dose to 50 mg twice daily when coadministered with CYP3A4 inhibitors such as ketoconazole, itraconazole, erythromycin, and diltiazem, or CYP2C19 inhibitors such as ticlopidine, fluconazole, and omeprazole
Source: US FDA prescribing information
Cilostazol tablets are contraindicated in patients with: Heart failure of any severity: Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. Hypersensitivity to cilostazol or any components of cilostazol tablets (e.g., anaphylaxis, angioedema) Heart failure of any severity. Hypersensitivity to cilostazol or any components of cilostazol tablets
Source: US FDA prescribing information
Boxed warning (contraindicated in heart failure patients): Cilostazol tablets are contraindicated in patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV heart failure. Risks of tachycardia, palpitation, tachyarrhythmia or hypotension. Risks of exacerbations of angina pectoris or myocardial infarction in patients with a history of ischemic heart disease. Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum. Risks of thrombocytopenia or leukopenia progressing to agranulocytosis- monitor platelets and white blood cell counts. Avoid use in patients with hemostatic disorders or active pathologic bleeding
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the labeling: Patients with Heart Failure Tachycardia Left Ventricular Outflow Tract Obstruction Hematologic Adverse Reactions Hemostatic Disorders or Active Pathologic Bleeding Most common adverse reactions greater than or equal to 2% and at least twice that for placebo in patients on 100 mg twice daily are headache, diarrhea, abnormal stools, and palpitation
Source: US FDA prescribing information
Strong and moderate CYP3A4 and CYP2C19 inhibitors: Increase exposure to cilostazol tablets. Reduce cilostazol tablets dose Inhibitors of CYP3A4 or CYP2C19 Inhibitors of CYP3A4: Coadministration of strong (e.g., ketoconazole) and moderate (e.g., erythromycin, diltiazem and grapefruit juice) CYP3A4 inhibitors can increase exposure to cilostazol tablets. Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP3A4. Inhibitors of CYP2C19: Coadministration with CYP2C19 inhibitors (e.g., omeprazole) increases systemic exposure of cilostazol tablets active metabolites. Reduce cilostazol tablets dose to 50 mg twice daily when coadministered with strong or moderate inhibitors of CYP2C19.
Source: US FDA prescribing information
Storage and handling Store at 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Cilostazol, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Cilostazol 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Cilostazol 50 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 15 January 1999 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Cilostazol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 2 presentations of Cilostazol and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Cilostazol on 15 January 1999, according to Drugs@FDA.
No listed presentation of Cilostazol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Cilostazol is classified under ATC code B01AC23 (Cilostazol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.